Ocuphire Pharma
commercial activities in | Ocuphire Pharma
Company
Deck Type
Deck date
January 2022
Slide
69 of 114
Related slides by other companies
AstraZeneca
Results
November 2023
capital allocation capital allocation strategy unchanged investments to drive future growth reinvestment in the business free post currently projects in phase development investments behind launches in new indications and strengthening leadership in existing therapy areas continued investments in new technologies and platforms including cell and gene therapies progressive dividend policy value accretive deals continue to leverage partnerships to drive innovation and bring medicines to markets priority remains in our business new approvals in major markets | AstraZeneca
DICE Therapeutics
Results
March 2023
key from phase efficacy results dice | DICE Therapeutics
G Medical Innovations
IPO
February 2023
the at home testing kit market our kit developments | G Medical Innovations
BAT
Results
February 2024
encouraging progress with regulatory changes a | BAT
Other recent decks by Ocuphire Pharma
See all presentations (10 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
May 2023
Results
January 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io